Adverts

Open Access Articles- Top Results for Nepadutant

Nepadutant

</th></tr></th></tr>
Nepadutant
File:Nepadutant.svg
Systematic (IUPAC) name
(2S)-2-[[(3S,6S,9S,12S)-12-[[(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid
Clinical data
Injection[1][2]
Pharmacokinetic data
Bioavailability <3% (oral)[1]
Half-life 44 minutes (IV)[1]
Identifiers
183747-35-5
None
PubChem CID 3086682
ChemSpider 2343247
Chemical data
Formula C45H60N10O14
965.016 g/mol

Nepadutant (INN) (code name MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK2 receptor antagonist.[2][3][4] It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.[3][5][6]

See also

References

  1. ^ a b c Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1999. pp. 56–. ISBN 978-0-08-058378-5. 
  2. ^ a b Peter Holzer (17 June 2004). Tachykinins. Springer. pp. 224–226. ISBN 978-3-540-20690-3. 
  3. ^ a b Vera Regitz-Zagrosek (2 October 2012). Sex and Gender Differences in Pharmacology. Springer Science & Business Media. pp. 489–. ISBN 978-3-642-30726-3. 
  4. ^ Royal Society of Chemistry (Great Britain) (January 2003). Amino Acids, Peptides and Proteins. Royal Society of Chemistry. ISBN 978-0-85404-242-5. 
  5. ^ Barbara Frank (29 June 2011). Women's Issues in Gastroenterology, An Issue of Gastroenterology Clinics. Elsevier Health Sciences. pp. 54–55. ISBN 1-4557-1220-5. 
  6. ^ Gabor Jancso (27 November 2008). Neurogenic Inflammation in Health and Disease. Elsevier. pp. 297–. ISBN 978-0-444-53229-9. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.